BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martelli AM, Buontempo F, McCubrey JA. Drug discovery targeting the mTOR pathway. Clin Sci (Lond) 2018;132:543-68. [PMID: 29523752 DOI: 10.1042/CS20171158] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang F, Sun S, Wang C, Haas M, Yeo S, Guan JL. Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation. Br J Cancer 2020;122:1791-802. [PMID: 32336756 DOI: 10.1038/s41416-020-0839-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
3 Shams R, Ito Y, Miyatake H. Mapping of mTOR drug targets: Featured platforms for anti-cancer drug discovery. Pharmacol Ther 2021;:108012. [PMID: 34624427 DOI: 10.1016/j.pharmthera.2021.108012] [Reference Citation Analysis]
4 He T, Li W, Song Y, Li Z, Tang Y, Zhang Z, Yang GY. Sestrin2 regulates microglia polarization through mTOR-mediated autophagic flux to attenuate inflammation during experimental brain ischemia. J Neuroinflammation 2020;17:329. [PMID: 33153476 DOI: 10.1186/s12974-020-01987-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
5 Martelli AM, Paganelli F, Fazio A, Bazzichetto C, Conciatori F, McCubrey JA. The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. Cancers (Basel) 2019;11:E629. [PMID: 31064074 DOI: 10.3390/cancers11050629] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
6 Bolourian A, Mojtahedi Z. Obesity and COVID-19: The mTOR pathway as a possible culprit. Obes Rev 2020;21:e13084. [PMID: 32578354 DOI: 10.1111/obr.13084] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
7 Dai Q, Zhou D, Xu L, Song X. Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats. Drug Des Devel Ther 2018;12:4095-105. [PMID: 30584274 DOI: 10.2147/DDDT.S175763] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 9.8] [Reference Citation Analysis]
8 He L, Fei DL, Nagiec MJ, Mutvei AP, Lamprakis A, Kim BY, Blenis J. Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to rapamycin. Proc Natl Acad Sci U S A 2019;116:19523-9. [PMID: 31492813 DOI: 10.1073/pnas.1902397116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wei X, Luo L, Chen J. Roles of mTOR Signaling in Tissue Regeneration. Cells 2019;8:E1075. [PMID: 31547370 DOI: 10.3390/cells8091075] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
10 Gupta MB, Jansson T. Novel roles of mechanistic target of rapamycin signaling in regulating fetal growth†. Biol Reprod 2019;100:872-84. [PMID: 30476008 DOI: 10.1093/biolre/ioy249] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
11 Viana SD, Reis F, Alves R. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. Oxid Med Cell Longev 2018;2018:3693625. [PMID: 30510618 DOI: 10.1155/2018/3693625] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
12 Belenchia AM, Gavini MP, Toedebusch RG, DeMarco VG, Pulakat L. Comparison of Cardiac miRNA Transcriptomes Induced by Diabetes and Rapamycin Treatment and Identification of a Rapamycin-Associated Cardiac MicroRNA Signature. Oxid Med Cell Longev. 2018;2018:8364608. [PMID: 30647817 DOI: 10.1155/2018/8364608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Wen Y, Zhang G, Liu L, Zhang P, lin L, Mei R, Zhang F, Chen Y, Li R. HAP1 interacts with 14-3-3 to regulate epileptic seizure via GABAAR-mediated inhibitory synaptic transmission in pentylenetetrazole rat model. Neuroscience Research 2022. [DOI: 10.1016/j.neures.2022.05.006] [Reference Citation Analysis]
14 Gil D, Laidler P, Zarzycka M, Dulińska-Litewka J. Inhibition Effect of Chloroquine and Integrin-Linked Kinase Knockdown on Translation in Melanoma Cells. Int J Mol Sci 2021;22:3682. [PMID: 33916175 DOI: 10.3390/ijms22073682] [Reference Citation Analysis]
15 Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Xu M, Su T, Che L, Wang J, Evert M, Calvisi DF, Chen X. Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E930. [PMID: 31277283 DOI: 10.3390/cancers11070930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Li Y, Zhao J, Wu X, Zhang Y, Jin Y, Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY) 2021;13:5442-60. [PMID: 33582655 DOI: 10.18632/aging.202474] [Reference Citation Analysis]
17 Zulkipli NN, Zakaria R, Long I, Abdullah SF, Muhammad EF, Wahab HA, Sasongko TH. In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors. Molecules 2020;25:E3991. [PMID: 32887218 DOI: 10.3390/molecules25173991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM. Targeting mTOR in Acute Lymphoblastic Leukemia. Cells 2019;8:E190. [PMID: 30795552 DOI: 10.3390/cells8020190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
19 Wei L, Zhou Q, Tian H, Su Y, Fu GH, Sun T. Integrin β3 promotes cardiomyocyte proliferation and attenuates hypoxia-induced apoptosis via regulating the PTEN/Akt/mTOR and ERK1/2 pathways. Int J Biol Sci 2020;16:644-54. [PMID: 32025212 DOI: 10.7150/ijbs.39414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
20 Basile MS, Cavalli E, McCubrey J, Hernández-Bello J, Muñoz-Valle JF, Fagone P, Nicoletti F. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. Drug Discov Today 2021:S1359-6446(21)00480-3. [PMID: 34763066 DOI: 10.1016/j.drudis.2021.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
21 Teh JLF, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso J, Aplin AE. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Mol Cancer Ther 2020;19:1719-26. [PMID: 32430489 DOI: 10.1158/1535-7163.MCT-19-1016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 2019;25:6429-42. [PMID: 31439581 DOI: 10.1158/1078-0432.CCR-19-0836] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
23 Hashimoto A, Handa H, Hata S, Tsutaho A, Yoshida T, Hirano S, Hashimoto S, Sabe H. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. Cell Commun Signal 2021;19:54. [PMID: 34001163 DOI: 10.1186/s12964-021-00733-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Azeez NA, Deepa VS, Sivapriya V. Phytosomes: emergent promising nano vesicular drug delivery system for targeted tumor therapy. Adv Nat Sci: Nanosci Nanotechnol 2018;9:033001. [DOI: 10.1088/2043-6254/aadc50] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
25 Gornowicz A, Szymanowski W, Bielawski K, Kałuża Z, Michalak O, Bielawska A. Mucin 1 as a Molecular Target of a Novel Diisoquinoline Derivative Combined with Anti-MUC1 Antibody in AGS Gastric Cancer Cells. Molecules 2021;26:6504. [PMID: 34770912 DOI: 10.3390/molecules26216504] [Reference Citation Analysis]
26 Gravina GL, Mancini A, Colapietro A, Delle Monache S, Sferra R, Pompili S, Vitale F, Martellucci S, Marampon F, Mattei V, Biordi L, Sherris D, Festuccia C. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. Cancers (Basel) 2019;11:E1604. [PMID: 31640252 DOI: 10.3390/cancers11101604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Afonso J, Santos LL, Longatto-Filho A, Baltazar F. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nat Rev Urol 2020;17:77-106. [PMID: 31953517 DOI: 10.1038/s41585-019-0263-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
28 Muñoz-Muñoz PLA, Mares-Alejandre RE, Meléndez-López SG, Ramos-Ibarra MA. Bioinformatic Analysis of Two TOR (Target of Rapamycin)-Like Proteins Encoded by Entamoeba histolytica Revealed Structural Similarities with Functional Homologs. Genes (Basel) 2021;12:1139. [PMID: 34440318 DOI: 10.3390/genes12081139] [Reference Citation Analysis]
29 Evangelisti C, Chiarini F, McCubrey JA, Martelli AM. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. Int J Mol Sci 2018;19:E1878. [PMID: 29949919 DOI: 10.3390/ijms19071878] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
30 Mortazavi M, Moosavi F, Martini M, Giovannetti E, Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol 2022;:103749. [PMID: 35728737 DOI: 10.1016/j.critrevonc.2022.103749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Magri J, Gasparetto A, Conti L, Calautti E, Cossu C, Ruiu R, Barutello G, Cavallo F. Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. Cells 2021;10:108. [PMID: 33430127 DOI: 10.3390/cells10010108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Schaufelberger M, Galbier F, Herger A, de Brito Francisco R, Roffler S, Clement G, Diet A, Hörtensteiner S, Wicker T, Ringli C. Mutations in the Arabidopsis ROL17/isopropylmalate synthase 1 locus alter amino acid content, modify the TOR network, and suppress the root hair cell development mutant lrx1. J Exp Bot 2019;70:2313-23. [PMID: 30753668 DOI: 10.1093/jxb/ery463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
33 Florey O, Overholtzer M. Macropinocytosis and autophagy crosstalk in nutrient scavenging. Philos Trans R Soc Lond B Biol Sci 2019;374:20180154. [PMID: 30967004 DOI: 10.1098/rstb.2018.0154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]